New Thread

Ctrl

I

Acasti Pharma Inc. Stock Price: Quote, Forecast, Splits & News (ACST)

Perplexity Finance

/

Company Profile

Grace Therapeutics, Inc. Price & Performance (GRCE)

Stock Performance

Updated Apr 24, 8:00 PM UTC

Grace Therapeutics, Inc.

$2.38USD

+$0.09 (+3.93%)

After Hours

-$0.08 (-3.36%)

Open

$2.30

Market Cap

$32.65M

Year High

$4.97

High

$2.38

P/E Ratio

-1.6

Year Low

$1.75

Low

$2.28

Dividend Yield

0.00%

Volume

9.64K

What's Happening

Related

Financial information provided by Financial Modeling Prep. Options data provided by Unusual Whales. Live transcripts provided by Quartr. Reported revenue and EPS data from Earnings powered by FinChat.io. All data is provided for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. · See all tickers.

Overview
Latest News
Earnings
Income Statement
Cash Flow
Balance Sheet
Related

Go Deeper

How will the recent positive Phase 3 results for GTX-104 impact Acasti Pharma's chances of FDA approval and future revenue?
What are the implications of Acasti Pharma's corporate name change to Grace Therapeutics for its brand and investor confidence?
Given the stock's sharp decline to a 52-week low, what are the main internal challenges contributing to this volatility?
How might the company's strong liquidity but rapid cash burn affect its ability to fund ongoing drug development and commercialization?
What is the outlook for Acasti's de-prioritized drug candidates, GTX-102 and GTX-101, in terms of potential out-licensing or sale?

Latest News

Grace Therapeutics Gains FDA Alignment for GTx-104 NDA Submission
Apr 9, 2025
Grace Therapeutics has secured positive feedback from the FDA regarding its planned New Drug Application for GTx-104, an IV nimodipine formulation targeting aneurysmal subarachnoid hemorrhage. The company expects to file its NDA in Q2 2025, positioning GTx-104 as a potential innovation in stroke care after decades of limited progress.12
OS Therapies Advances Cancer Immunotherapy Pipeline with New FDA Engagement
Apr 9, 2025
OS Therapies is seeking a formal FDA meeting to discuss surrogate endpoints for accelerated approval of OST-HER2, its immunotherapy candidate for lung metastatic osteosarcoma. Recent positive preclinical data and acquisitions have strengthened the company’s position in cancer immunotherapy, potentially boosting investor confidence and future market share.3
Corporate Actions Reshape Shareholder Positions in Multiple Biotech Firms
Dec 20, 2021
Recent corporate moves include reverse splits for Outset Medical, Aditxt, and Blue Hat Interactive, while Syros Pharmaceuticals and BurgerFi International faced delisting or liquidation. These actions impact shareholder equity and illustrate volatility in the biotech and specialty finance sectors, emphasizing the importance of monitoring corporate restructuring events.4